Kymera Therapeutics, Inc. (KYMR) Stock: Price, Forecast & Analyst Target
Kymera Therapeutics, Inc. (KYMR) — MoonshotScore 26/100 (Weak band), calculated Nov 18, 2026. Price $115.31 (-3.42%), as of the Nov 20, 2026 trading session; market cap $9.84B. Expected results Feb 25, 2027.
Educational signal · not a buy or sell recommendation · How to read this
Market value / cash and short-term investments: 10.13× (cash as of Sep 30, 2026) · expected results Feb 25, 2027
Kymera Therapeutics, Inc. · KYMR · NASDAQ · Healthcare · Biotechnology
Research dated 2026-09-13 (results through Q2 FY2026; the quarter ended Sep 2026 not covered): Kymera Therapeutics develops small-molecule drug candidates that direct the body’s protein disposal machinery toward disease-causing proteins across immunology and oncology. Its value depends less on current reported revenue than on whether the degradation platform produces convincing clinical evidence before sustained research spending consumes too much of its financial cushion.
Price as of Nov 20, 2026
Key Statistics
MoonshotScore v2 · Kymera Therapeutics (KYMR)
WeakWhy this rating? Method, drivers & history
Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.
- Business Quality — Is this a genuinely good business?
- Financial Safety — Could this blow up on me?
- Valuation — Am I paying a fair price?
- Growth Durability — Is the growth real and likely to last?
- Momentum — Is the market already moving on this?
A strong balance sheet, but bottom-tier quality, stalling growth and a full valuation. The score also carries a risk penalty for losses on top of negative retained earnings. Business Quality: Thin; Financial Safety: Fortress; Valuation: Full; Growth Durability: Fading; Momentum: Surging.
- EPS beat 3 of the last 8 reports
- Altman Z 41.17 · Piotroski F 4
- ROE -27.3% · ROA -17.6% · current ratio 11.13
Holding back: weak fundamentals, soft growth
Helping: balance-sheet strength, positive momentum
What has the MoonshotScore done over time?
| Recorded | Score | Band |
|---|---|---|
| 26 | Weak | |
| 26 | Weak | |
| 26 | Weak | |
| 26 | Weak | |
| 26 | Weak | |
| 26 | Weak |
Daily score refresh is delayed. This is the last recorded calculation.
Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.
Computed · How the MoonshotScore is computed →
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $115.31 | |
| Change on the day | -3.42% | |
| 52-week range | $62.91–$142.92 | |
| Market capitalisation | $9.84B | — |
| Shares traded on the day | 1.25M | |
| Beta (volatility vs the S&P 500) | 2.03 |
Price & events
Triangles mark reported quarters on the line: pointing up is above the recorded estimate, down is below, a diamond means no estimate on file. Numbers key to the dated list. Point at or tab to any week for its close.
Events behind the price
- · Earnings results · below the recorded estimate
- · Earnings results · above the recorded estimate
- · Earnings results · above the recorded estimate
- · Earnings results · below the recorded estimate
Results dates follow the earnings feed; call dates follow the transcript provider. Nearby dates do not establish that an event caused a price move.
Upcoming events
How to read these dates
Estimated dates can change.
Other perspectives
Council score for Kymera Therapeutics (KYMR): perspectives
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
5-Factor Breakdown
Legends Council
6 lenses, 0 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Nov 18, 2026 · older than the 27 hours refresh window; not a current reading
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Nov 18, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
On Nov 18, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.
Readings on this page are from Nov 21, 2026, except a card that shows its own read date.
What is Kymera Therapeutics (KYMR), and what does it report?
Short answer · as of
Kymera is a clinical-stage drug developer, not a medicine-volume business. Its candidates are designed to remove pathogenic proteins rather than merely inhibit them, with programs spanning inflammatory disorders, blood cancers, solid tumors, autoimmune disease and fibrosis.
Research dated 2026-09-13 (results through Q2 FY2026; the quarter ended Sep 2026 not covered).
Reported revenue therefore should not be read as patient demand. The financial statements currently measure development economics: volatile revenue alongside heavy research spending, recurring operating losses and no corresponding commercial sales trend.
What do the latest results show for Kymera Therapeutics (KYMR)?
Research dated 2026-09-13 (results through Q2 FY2026; the quarter ended Sep 2026 not covered).
The latest reported period brought a sharp revenue increase, a narrower operating loss and a less negative per-share result even as research spending climbed. Operating cash outflow also improved from the preceding period, though it remained substantial.
Recent reports reversed the earlier pattern of shortfalls by exceeding revenue and loss expectations. Because the pipeline remains in development, that improvement is better understood as a change in reported development economics than as evidence of rising medicine demand.
Where is operating spending going?
Revenue alongside research and development, selling, general and administrative expenses, and the FMP standardized operating result.
- Latest quarter · revenue
- $0.00 Sep 30, 2026
- Latest quarter · R&D
- $128.51M Sep 30, 2026
- Latest quarter · SG&A
- $18.72M Sep 30, 2026
- Latest quarter · FMP standardized operating result
- −$147.23M Sep 30, 2026
| Period end | Revenue | R&D | SG&A | FMP standardized operating result |
|---|---|---|---|---|
| Sep 30, 2026 | $0.00 | $128.51M | $18.72M | −$147.23M |
| Jun 30, 2026 | $65.00M | $119.48M | $21.13M | −$75.61M |
| Mar 31, 2026 | $34.37M | $98.16M | $20.36M | −$84.15M |
| Dec 31, 2025 | $2.86M | $83.86M | $16.95M | −$97.90M |
How to read these figures
Amounts are in US dollars. The operating result is Financial Modeling Prep’s standardized figure, so it can differ from the operating line in the company’s filing. It is not net income or cash flow.
Did results meet expectations?
Reported earnings and revenue alongside the estimates recorded by the provider.
- Latest report · revenue
- $1.35M Oct 29, 2026
- Latest report · revenue estimate
- $3.28M Oct 29, 2026
- Latest report · revenue vs estimate
- Below estimate Oct 29, 2026
- Latest report · EPS vs estimate
- Below estimate Oct 29, 2026
| Report date | Revenue · reported | Revenue · estimate | EPS · reported | EPS · estimate |
|---|---|---|---|---|
| Oct 29, 2026 | $1.35M | $3.28M | −$1.3200 | −$1.2600 |
| Aug 5, 2026 | $65.00M | $32.78M | −$0.6200 | −$0.7126 |
| Apr 30, 2026 | $34.37M | $8.27M | −$0.7100 | −$0.8900 |
| Feb 26, 2026 | $2.87M | $15.05M | −$0.9700 | −$0.7837 |
How to read these figures
Dates are when results were reported, not quarter ends. Amounts are in US dollars; EPS is per share. The source does not say whether EPS is basic, diluted or adjusted, so it can differ from the EPS in the income statement.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Sep 2026 | $0 | -$132M | -$1.32 (diluted) |
| Q2 FY2026 | $65M | -$61M | -$0.62 (diluted) |
| Q1 FY2026 | $34M | -$69M | -$0.71 (diluted) |
| Q4 FY2025 | $3M | -$87M | -$0.98 (diluted) |
What are the financial strengths and risks for Kymera Therapeutics (KYMR)?
Short answer
Cash and short-term investments were $971.21M at the Sep 30, 2026 balance-sheet date. Operating cash flow was −$77.91M for the quarter ended Sep 30, 2026, meaning operations used cash. These figures do not establish a cash runway.
Research dated 2026-09-13 (results through Q2 FY2026; the quarter ended Sep 2026 not covered).
Cash and investments dwarf debt, total liabilities and recent operating cash outflows. Liquidity ratios and the distress screen reinforce that near-term solvency is not the immediate constraint, although much of the broader resource total sits in long-term investments rather than cash and short-term holdings.
The vulnerability is persistent consumption of capital while research spending rises. Expected losses remain deep, and market value stands far above net cash, so clinical disappointment could remove anticipated pipeline value while leaving the expense base and cash burn intact.
Data-derived red flags
- Negative return on equity (-27.3%) — the business is not currently generating profit on shareholder capital.
- Inconsistent delivery — missed Wall Street EPS estimates in 5 of the last 8 reported quarters.
How much cash does the business generate or use?
Quarterly operating cash flow shows cash generated or used by operations.
- Latest quarter · operating cash flow
- −$77.91M Sep 30, 2026
- Previous quarter · operating cash flow
- −$54.06M Jun 30, 2026
| Period end | Operating cash flow | Capital expenditure (reported) |
|---|---|---|
| Sep 30, 2026 | −$77.91M | −$310,000 |
| Jun 30, 2026 | −$54.06M | −$470,000 |
| Mar 31, 2026 | −$88.84M | −$430,000 |
| Dec 31, 2025 | −$66.75M | −$110,000 |
How to read these figures
Amounts are in US dollars. Negative operating cash flow means the business used cash. Capital spending is shown as reported; we do not combine it into a free-cash-flow or runway estimate. The bars share one scale.
What should you watch next at Kymera Therapeutics (KYMR)?
Short answer · as of
The next earnings report is expected on Feb 25, 2027.
Research dated 2026-09-13 (results through Q2 FY2026; the quarter ended Sep 2026 not covered).
The next earnings release will test whether reported revenue falls back after its recent surge and whether the loss deepens as consensus expects. More durable observations are the direction of research spending, operating cash outflow and the split between readily available liquidity and longer-term investments.
Clinical progress across Kymera’s immunology and oncology programs matters more than quarterly revenue noise because the valuation assigns substantial worth beyond net cash. Recent disclosed insider activity consisted of sales and other transactions, with no purchases, making subsequent filings worth monitoring as a secondary signal rather than evidence about trial outcomes.
How does Kymera Therapeutics compare with its peers?
Short answer
Kymera Therapeutics's score ranks 12th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.
Research dated 2026-09-13 (results through Q2 FY2026; the quarter ended Sep 2026 not covered).
Kymera differs from commercial biotechnology companies because its current revenue does not represent prescription volume; the economic asset is a protein-degradation platform and the clinical portfolio built from it. The same mechanism is being applied across inflammatory disease and cancer, giving the company broader biological exposure than a developer centered on a narrowly defined indication.
Compared with cash-burning drug developers, Kymera combines substantial investment resources with light debt. That financial flexibility supports development, but the valuation still depends predominantly on future clinical and strategic value rather than present revenue or cash generation.
| Company | Price | Market value | Score |
|---|---|---|---|
| $93.53 Nov 19, 2026 | $7.35B | 98 5-pillar Nov 18, 2026 | |
| $64.63 Nov 20, 2026 | $15.8B | 98 5-pillar Nov 18, 2026 | |
| $315.82 Nov 19, 2026 | $9.36B | 96 5-pillar Nov 18, 2026 | |
| $91.35 Nov 20, 2026 | $10.4B | 95 5-pillar Nov 18, 2026 | |
| $72.67 Nov 20, 2026 | $11.4B | 92 5-pillar Nov 18, 2026 | |
| $64.98 Nov 19, 2026 | $7.11B | 91 5-pillar Nov 18, 2026 | |
| $64.88 Nov 19, 2026 | $9.81B | 90 5-pillar Nov 18, 2026 | |
| $124.02 Nov 19, 2026 | $8.09B | 88 5-pillar Nov 18, 2026 | |
| $97.57 Nov 19, 2026 | $6.62B | 67 5-pillar Nov 18, 2026 | |
| $151.02 Nov 19, 2026 | $6.13B | 64 5-pillar Nov 18, 2026 | |
| $310.90 Nov 19, 2026 | $8.69B | 60 5-pillar Nov 18, 2026 | |
| Kymera Therapeutics (KYMR) — this page | $115.31 | $9.84B | 26 |
| $32.52 Nov 19, 2026 | $6.73B | 25 5-pillar Nov 18, 2026 |
Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.
The records behind this page
Analyst targets & estimates
What analysts have on file
- Price target, low to high
- $115.00 – $180.00
- Consensus target
- $141.53
- Median target
- $140.00
Consensus record · Captured .
Measured against a quoted price of $115.31 (as of Nov 20, 2026).
Insider activity
Form 4 records via FMP · Of the newest 100 records, those within the last 180 days, newest dated Oct 1, 2026
- Transactions
- 99
- Identified insiders
- 7
- Purchases
- 0
- Sales
- 88
- Other transactions
- 11
Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.
Who holds the shares?
Institutional ownership reported through 13F filings.
- Reporting holders
- 316 Period end Sep 30, 2026
- Previous quarter · holders
- 295 Prior to period end Sep 30, 2026
| Holders in provider snapshot | Shares |
|---|---|
| Fmr LLC | 12,568,921 |
| Price T Rowe Associates INC /Md/ | 8,725,908 |
| Baker Bros. Advisors LP | 8,657,242 |
| Avoro Capital Advisors LLC | 7,474,747 |
| Blackrock, INC. | 5,825,416 |
Tracked investors
Which of the 16 named investors we follow held KYMR in their latest 13F filing, and what they did against the filing before it.
None of the 16 tracked investors reported KYMR in their latest 13F filing.
How to read these figures
These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Holder snapshot as of Sep 30, 2026. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.
What has been published about Kymera Therapeutics (KYMR)?
- Kymera Therapeutics (KYMR) Stock May Be Overvalued Following Positive KT 579 Data
- Barclays Maintains Overweight Rating and Raises Price Target for Kymera Therapeutics
- Barclays Maintains Overweight on Kymera Therapeutics, Raises Price Target to $170
- Truist Securities Reiterates Buy on Kymera Therapeutics, Raises Price Target to $150
What Investors Ask About Kymera Therapeutics (KYMR) — Healthcare
Research dated 2026-09-13 (results through Q2 FY2026; the quarter ended Sep 2026 not covered); the full attribution is under Sources. The last 2 questions are answered from this page's own dated data, not from the research.
What does Kymera’s targeted protein degradation platform do?
It uses small molecules to recruit the body’s inherent protein disposal system and selectively eliminate proteins associated with disease. Kymera applies that mechanism across inflammatory disorders, cancer, autoimmune disease and fibrosis.
How does IRAKIMiD fit Kymera’s oncology pipeline?
IRAKIMiD is designed for diffuse large B cell lymphoma carrying a particular mutation. It sits alongside other Kymera programs aimed at blood cancers and solid tumors.
Why can Kymera revenue rise while its medicines remain in development?
Kymera’s pipeline remains in clinical development, so reported revenue is not a measure of prescription demand. The latest increase improved reported losses, but research spending and operating cash outflow remained substantial.
Why are immunology and oncology linked inside Kymera’s pipeline?
Kymera is applying the same underlying protein-removal approach to different disease-causing targets. That creates a shared platform across inflammatory conditions, blood cancers, solid tumors, autoimmune disease and fibrosis, while each program retains its own clinical risk.
What is the KYMR stock price today?
The last price recorded for Kymera Therapeutics, Inc. (KYMR), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What is the KYMR price target?
The analyst consensus price target for Kymera Therapeutics, Inc. (KYMR), with its range and the date it was captured from FMP, is listed under Analyst targets & estimates on this page. Targets are analyst opinions and change often; they are not a Stock Expert AI forecast.
Research written by Codex (gpt-5.6-sol) on 2026-09-13. AI-authored analysis; source dates are listed under Sources. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources: the source register lists the 75 figures on this page — 1 from SEC filings and earnings calls, 66 from Financial Modeling Prep (FMP), 4 with no recorded source, 3 computed by us, formula shown in the register and 1 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.
Publication details and research sources
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com